Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV
Should Investors Be Worried About Dividend King AbbVie?
04:42am, Monday, 28'th Apr 2025
Nearly everything looked great with AbbVie's (ABBV 3.10%) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease dr
Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results
11:40pm, Sunday, 27'th Apr 2025
As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its onco
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
06:05pm, Saturday, 26'th Apr 2025
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong un
Why AbbVie Stock Topped the Market Today
05:17pm, Friday, 25'th Apr 2025
A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (ABBV 3.10%) stock an investor darling on Friday. The pharmaceutical company's performance
AbbVie's First Quarter Beat And Raise Leaves Room For More
05:17pm, Friday, 25'th Apr 2025
AbbVie Inc. beat first-quarter revenue and EPS estimates and raised the full-year EPS guidance by $0.10 and revenue guidance by $700 million. Skyrizi and Rinvoq drove the ABBV Q1 beat with exceptional
AbbVie: Q1 Earnings Reinforce Positive Momentum
04:00pm, Friday, 25'th Apr 2025
AbbVie Inc.'s Q1 2025 results exceeded expectations on the earnings front, but the key question is whether the stock is an immediate buy. It saw an accelerated 8.4% YoY revenue growth, driven by stron
Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing
02:30pm, Friday, 25'th Apr 2025
AbbVie Inc. took a little shot at the Trump administration's trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing.
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
02:20pm, Friday, 25'th Apr 2025
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
02:00pm, Friday, 25'th Apr 2025
AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's pate
AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
01:26pm, Friday, 25'th Apr 2025
AbbVie (ABBV) on Friday reported first-quarter results that came in above analysts' estimates, and lifted its full-year profit guidance.
AbbVie Inc. (ABBV) Q1 2025 Earnings Call Transcript
12:14pm, Friday, 25'th Apr 2025
AbbVie Inc. (NYSE:ABBV ) Q1 2025 - Earnings Conference Call April 25, 2025 9:00 PM ET Company Participants Liz Shea - Senior VP, IR Rob Michael - CEO Jeff Stewart - EVP, Chief Commercial Officer Roopa
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
10:51am, Friday, 25'th Apr 2025
AbbVie Inc.'s ABBV stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast.
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
10:35am, Friday, 25'th Apr 2025
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
2 Pharma Stocks Buzzing in the Options Pits After Earnings
10:32am, Friday, 25'th Apr 2025
Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings confessional this morning and last night.
